Table 2 Multivariate analysis for outcomes

Relapse

 Age (per 10 years)

0.95

0.744–1.217

0.69

 CR1 (reference)

1

 CR2+

1.69

0.72–3.95

0.22

 Advanced

8.04

3.76–17.19

<0.01

 Ph+ vs Ph−

1.09

0.53–2.24

0.80

 KPS ≥ 90%

2.02

0.95–4.29

0.06

 Female recipient

0.59

0.29–1.20

0.14

 Female D ≥ male R

0.39

0.18–0.84

0.01

 RIC vs MAC

1.32

0.67–2.5

0.41

 R CMV positive

1.11

0.45–2.75

0.81

 ATG vs PT-Cy

1.15

0.63–2.13

0.63

 PB vs BM

1.46

0.68–3.10

0.32

 Center (frailty)

0.94

 Age (per 10 years)

0.98

0.72–1.33

0.90

 CR1 (reference)

1

 CR2+

2.15

0.92–5.02

0.07

 Advanced

1.50

0.59–3.82

0.39

 Ph+ vs Ph−

1.45

0.61–3.42

0.39

 KPS ≥ 90%

0.23

0.10–0.52

<0.01

 Female recipient

1.26

0.52–3.04

0.59

 Female D ≥ male R

1.47

0.60–3.57

0.39

 RIC vs MAC

0.76

0.36–1.60

0.47

 R CMV positive

0.57

0.23–1.41

0.22

 ATG vs PT-Cy

1.79

0.90–3.55

0.09

 PB vs BM

2.56

1.14–5.74

0.02

 Center (frailty)

0.94

 Age (per 10 years)

0.98

0.82–1.18

0.89

CR1 (reference)

1

 CR2+

1.91

1.06–3.41

0.02

 Advanced

3.81

2.17–6.67

<0.01

 Ph + vs Ph−

1.13

0.66–1.94

0.63

 KPS ≥ 90%

0.78

0.47–1.29

0.34

 Female recipient

0.77

0.45–1.32

0.35

 Female D ≥ male R

0.72

0.41–1.24

0.24

 RIC vs MAC

1.05

0.64–1.72

0.82

 R CMV positive

0.73

0.40–1.33

0.31

 ATG vs PT-Cy

1.32

0.84–2.06

0.21

 PB vs BM

1.81

1.06–3.09

0.02

 Center (frailty)

0.9

 Age (per 10 years)

1.02

0.84–1.22

0.82

 CR1 (reference)

1

 CR2+

2.22

1.22–4.03

<0.01

 Advanced

3.66

2.06–6.52

<0.01

 Ph + vs Ph−

1.16

0.67–2.01

0.58

 KPS ≥ 90%

0.62

0.37–1.02

0.06

 Female recipient

0.81

0.47–1.38

0.44

 Female D ≥ male R

0.76

0.43–1.35

0.36

 RIC vs MAC

0.91

0.56–1.48

0.71

 R CMV positive

0.81

0.43–1.51

0.51

 ATG vs PT-Cy

1.4

0.88–2.20

0.14

 PB vs BM

1.98

1.14–3.42

0.01

 Center (frailty)

0.92

 Age (per 10 years)

0.91

0.76–1.08

0.29

 CR1 (reference)

1

 CR2+

1.35

0.78–2.34

0.28

 Advanced

2.71

1.56–4.68

< 0.01

 Ph + vs Ph−

1.20

0.72–2.02

0.47

 KPS ≥ 90%

0.84

0.50–1.40

0.51

 Female recipient

0.70

0.42–1.18

0.18

 Female D ≥ male R

0.81

0.48–1.38

0.45

 RIC vs MAC

1.03

0.65–1.63

0.87

 R CMV positive

0.85

0.47–1.53

0.59

 ATG vs PT-Cy

1.04

0.67–1.61

0.85

 PB vs BM

1.82

1.10–3.01

0.01

 Center (frailty)

0.92

 Age (per 10 years)

0.75

0.56–1.00

0.05

 CR1 (reference)

1

 CR2+

1.45

0.696–3.024

0.32

 Advanced

0.76

0.29–2.0

0.59

 Ph + vs Ph−

1.15

0.52–2.55

0.72

 KPS ≥ 90%

0.80

0.33–1.93

0.63

 Female recipient

1.23

0.53–2.88

0.62

 Female D ≥ male R

1.84

0.82–4.13

0.13

 RIC vs MAC

0.46

0.23–0.93

0.03

 R CMV positive

1.28

0.43–3.78

0.65

 ATG vs PT-Cy

0.97

0.52–1.81

0.93

 PB vs BM

3.00

1.35–6.70

<0.01

 Center (frailty)

0.93

 Age (per 10 years)

0.97

0.69–1.37

0.89

 CR1 (reference)

1

 CR2+

0.58

0.20–1.71

0.33

 Advanced

0.62

0.20–1.90

0.40

 Ph + vs Ph−

0.86

0.33–2.20

0.75

 KPS 90%

0.68

0.26–1.77

0.43

 Female recipient

0.93

0.34–2.57

0.90

 Female D ≥ male R

1.38

0.48–3.94

0.54

 RIC vs MAC

0.94

0.38–2.36

0.91

 R CMV positive

0.51

0.16–1.56

0.24

 ATG vs PT-Cy

0.67

0.25–1.73

0.41

 PB vs BM

1.98

0.76–5.14

0.15

 Center (frailty)

0.13